LPAR1 and ischemic stroke: Indeed, our previous study has shown that inhibiting LPA1 activity by either a pharmacological antagonist or genetic deletion with a specific shRNA, can attenuate tMCAO-induced brain infarction and neurological deficits during the acute phase of ischemic stroke [12].